Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$32M
- +23.5% YoY · +2.3% QoQ
- EPS (diluted)
- −$0.39
- +25.0% YoY · +7.1% QoQ
Source: XBRL data from the Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 10-Q on SEC EDGAR. USD.
Atea Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved or product sales generated
- Operating loss $34.0M vs $45.6M YoY, operating margin not applicable
- HCV R&D $17.4M vs $30.2M, strongest program; HEV R&D $2.7M vs $0
- Cash and investments $191.2M; nine-month operating cash use $112.3M vs $103.8M
- C-FORWARD results expected Q1 2027, FDA NDA submission targeted Q2 2027; funding expected into mid-2028
Risk Factors
- New debt facility: November 2026 Hercules agreement adds $65.0 million funded debt, floating-rate interest, and $200.0 million total commitments
- Liquidity risk: $105.0 million of undrawn capacity requires milestones, while $30.0 million remains at lenders’ discretion
- Regulatory pricing risk: September 2026 Globe regulation may require Medicare Part B rebates based on most-favored-nation pricing
- Clinical risk: C-FORWARD Phase 3 results remain critical, with topline results anticipated in first-quarter 2027
- Financial condition: Nine-month 2026 net loss reached $110.5 million, with accumulated deficit of $633.1 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atea Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.